1. Eye Disease Prevalence Research Group (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564–572
2. Evans J, Wormald R (1996) Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 80:9–14
3. VanNewkirk M, Weih LM, McCarty CA, Taylor HR (2001) Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the visual impairment project. Ophthalmology 108:960–967
4. Bressler NM (2000) Age related macular degeneration. New hope for a common problem comes from photody- namic therapy. BMJ 321:1425–1427
5. Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122: 598–614
6. Beatty S, Koh H, Phil M, Henson D, Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45:115–134
7. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Rani- bizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431
8. Gupta OP, Brown GC, Brown MM (2007) Age-related macular degeneration: the costs to society and the patient. Curr Opin Ophthalmol 18:201–205
9. Minckler D (2000) Evidence-based ophthalmology series and content-based continuing medical education for the journal. Ophthalmology 107:9–10
10. Seddon JM, Ajani UA, Sperduto RD, Eye Disease Case- Control Study Group et al (1994) Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272:1413–1420
11. Snellen EL, Verbeek AL, Van Den Hoogen GW, Cruysberg JR, Hoyng CB (2002) Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol Scand 80:368–371
12. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO (1988) Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 128:700–710
13. VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, Palta M (1998) Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 148:204–214
14. Newsome DA, Swartz M, Leone MC, Elston RC, Miller E (1988) Oral zinc in macular degeneration. Arch Ophthalmol 106:192–198
15. Moriarty-Craige SE, Ha K-N et al (2007) Effects of long- term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. Am J Ophthalmol 143:206–211
16. Dietary Reference Intakes, Institute of Medicine of the National Academies website. 
17. The Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS Report No. 8. Arch Ophthalmol 119:1417–1436
18. Klein R, Peto T, Bird A et al (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 137:486–495
19. Omenn GS, Goodman GE, Thornquist MD et al (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155
20. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta 
21. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC, Klaver CC, Hofman A, de Jong PT (2005) Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 294:3101–3107
22. Evans JR (2006) Antioxidant vitamin and mineral supplements for slowing the progression of age related macular degeneration. Cochrane Database Syst Rev (2):CD000 254
23. Sujak A, Gabrielska J, Grudzinski W, Borc R et al (1999) Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects. Arch Biochem Biophys 371:301–307
24. Rosenthal JM, Kim J, Monastario F et al (2006) Dose- ranging study of lutein supplementation in persons aged 60 years or older. Invest Ophthalmol Vis Sci 47:5227–5233
25. Whitehead AJ, Mares JA, Danis RP (2006) Macular pigment: a review of current knowledge. Arch Ophthalmol 124:1038–1045
26. Moeller SM, Parekh N, Tinker L, CAREDS Research Study Group et al (2006) Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-Related Eye Disease Study (CAREDS): ancillary study of the Women’s Health Initiative. Arch Ophthalmol 124:1151–1162
27. Delcourt C, Carri `re I, Delage M, Barberger-Gateau P, Schalch W, the POLA Study Group (2006) Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA study. Invest Ophthalmol Vis Sci 47:2329–2335
28. Gale CR, Hall NF, Phillips DI, Martyn CN (2003) Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 44:2461–2465
29. Trumbo PR, Ellwood KC (2006) Lutein and zeaxanthin intakes and risk of age-related macular degeneration and cataracts: an evaluation using the Food and Drug Admin- istration’s evidence-based review system for health claims. Am J Clin Nutr 84:971–974
30. Coleman H, Chew E (2007) Nutritional supplementation in age-related macular degeneration. Curr Opinion Ophthalmol 18:220–223
31. AREDS2 website. 
32. Shao A, Hathcock JN (2006) Risk assessment for the carotenoids lutein and lycopene. Regul Toxicol Pharmacol 45:289–298
33. Mozaffarian D, Rimm EB (2006) Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296:1885–1899
34. Bang HO, Dyerberg J (1980) Lipid metabolism and ischaemic heart disease in Greenland Eskimos. In: Draper H (ed) Advances in nutrition research. Plenum Press, New York, pp 1–22
35. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N (2004) Association between C-reactive protein and age- related macular degeneration. JAMA 291:704–710
36. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308:421–424
37. Klein RJ, Zeiss C, Chew E et al (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308:385–389
38. Hageman GS, Anderson DH, Johnson LV et al (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102:7227–7232
39. Haines JL, Hauser MA, Schmidt S et al (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308:419–421
40. Horrocks LA, Yeo YK (1999) Health benefits of docosa- hexaenoic acid (DHA). Pharmacol Res 40:211–225
41. Hodge WG, Schachter HM, Barnes D et al (2006) Efficacy of x-3 fatty acids in preventing age-related macular degeneration: a systematic review. Ophthalmology 113: 1165–1173
42. Seddon JM, George S, Rosner B (2006) Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of age-related macular degeneration. Arch Ophthalmol 124:995–1001
43. Carroll DN, Roth MT (2002) Evidence for the cardiopro- tective effects of omega-3 fatty acids. Ann Pharmacother 36:1950–1956
44. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M (1996) Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Car- diol 77:31–36
45. Leaf A, Jorgensen MB, Jacobs AK et al (1994) Do fish oils prevent restenosis after coronary angioplasty? Circulation 90:2248–2257
46. Bender NK, Kraynak MA, Chiquette E, Linn WD, Clark GM, Bussey HI (1998) Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis 5:257–261